Drug Assignments and Reassignments

 

Drug Name Active Ingred Mfr Indication Approval
Date
AHFS Class NDA
Chem
Type*
Actemra® tocilizumab Genentech rheumatoid arthritis 1/20/2010 92:36 - Disease-modifying Antirheumatic Agents  
Ampyra® dalfampridine Acorda multiple sclerosis 1/22/2010 92:92 - Other Misc Therapeutic Agents  
Victoza® liraglutide Novo Nordisk type 2 diabetes 1/25/2010 68:20.06 - Incretin Mimetics  
Xiaflex® collagenase clostridium histolyticum Auxilium adult Dupuytren's contracture patients with a palpable cord 2/2/2010 44:00 - Enzymes  
VPRIV® velaglucerase alfa Shire type 1 Gaucher disease 2/26/2010 44:00 - Enzymes  
Carbaglu® carglumic acid Orphan Europe N-acetylglutamate synthase (NAGS) deficiency 3/18/2010 40:10 - Ammonia Detoxicants  
Asclera® polidocanol BioForm Medical small vericose veins 3/30/2010 24:16 - Sclerosing Agents  
Iprivask® desirudin Canyon prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery 3/30/2010 (launched) 20:12.04.12 - Direct Thrombin Inhibitors  
Provenge® sipuleucel-T Dendreon treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer 4/29/2010 26:00 - Cellular Therapy  
Natazia® estradiol valerate/dienogest Bayer contraceptive 5/6/2010 68:12 - Contraceptive  
Prolia®, XGEVA® denosumab Amgen treatment of postmenopausal women with osteoporosis at high risk for fracture 6/1/2010 92:24 - Bone Resorption Inhibitors  
Jalyn® dutasteride/tamsulosin GSK benign prostatic hyperplasia 6/14/2010 92:08 - 5-α-Reductase Inhibitors; 12:16.04.12 - Selective α1 Adrenergic Blocking Agents  
Jevtana® cabazitaxel Sanofi Aventis hormone-refractory metastatic prostate cancer 6/17/2010 10:00 - Antineoplastic Agents  
Vaprisol®; Samsca® conivaptan; tolvaptan Astellas; Otsuka euvolemic and hypervolemic hyponatremia 7/1/2010 from 40:28.92 to new class 40:28.28 - Vasopressin Antagonists  
Lymphazurin® isosulfan blue Mylan contrast agent for the delineation of lymphatic vessels 7/20/2010 36:46 - Lymphatic System
Lastacaft® alcaftadine Vistakon allergic conjunctivitis 7/28/2010 52:02 - Antiallergic Agents (EENT)
Xeomin® incobotulinumtoxinA Merz cervical dystonia, blepharospasm 7/30/2010 92:92 - Other Misc Therapeutic Agents  
Ella® ulipristal Watson emergency contraceptive 8/13/2010 68:12 - Contraceptives  
Krystexxa® pegloticase Savient chronic gout 9/14/2010 92:16 - Antigout Agents  
Gilenya® fingolimod Novartis multiple sclerosis 9/21/2010 92:20 - Biologic Response Modifiers  
Aridol® mannitol Pharmaxis bronchial challenge test 10/5/2010 36:70 - Respiratory Function (new class)  
Pradaxa® dabigatran Boehringer Ingelheim preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation 10/19/2010 20:12.04.12 - Direct Thrombin Inhibitors
Latuda® lurasidone Sunovion schizophrenia 10/28/2010 28:16.08.04 - Atypical Antipsychotics  
Teflaro® ceftaroline Cerexa acute skin and skin structure infections and community-acquired pneumonia caused by susceptible strains, including MRSA 10/29/2010 8:12.06.20 - Fifth Generation Cephalosporins (new class)  
Nuedexta® dextromethorphan/
quinidine
Avanir pseudobulbar affect (PBA) 10/29/2010 28:92 - Central Nervous System Agents, Misc  
Egrifta® tesamorelin Thera-technologies lipodystrophy in HIV patients 11/10/2010 68:30.04 - Somatotropin Agonists  
Halaven® eribulin EISAI metastatic breast cancer 11/15/2010 10:00 - Antineoplastic Agents  

Drug Classification Changes

 

AHFS Class Retired Change Description
12:16.04 - α-Adrenergic Blocking Agents - New classification
12:16.04.04 - Non-selective α-Adrenergic Blocking Agents - New classification
12:16.04.08 - Non-selective α1-Adrenergic Blocking Agents - New classification
12:16.04.12 - Selective α1-Adrenergic Blocking Agents - New classification
12:16.08 - β-Adrenergic Blocking Agents - New classification
12:16.08.04 - Non-selective β-Adrenergic Blocking Agents - New classification
12:16.08.08 - Selective β-Adrenergic Blocking Agents - New classification
28:40 - Fibromyalgia Agents - New classification